Carmen Bergom, MD, PhD, MPhil
Associate Professor, Radiation Oncology and Pharmacology and Toxicology
PhD, Cell Biology, Medical College of Wisconsin, Milwaukee, WI 2006
MPhil, Epidemiology, Cambridge University, Cambridge, UK, 1999
SB, Chemical Engineering and Biology, MIT, Cambridge, MA, 1988
Internal Medicine, Saint Luke's Hospital, Milwaukee, Wisconsin (2009)
Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin (2013)
Radiation Oncology, American Board of Radiology (2014)
The Bergom laboratory embraces collaborative research and also prioritizes the education and training of students and post-doctoral fellows.
This diagram outlines the two main arms of the laboratory (Figure 1).
We have a research program focusing on using unique genetic models and next generation sequencing to enhance the therapeutic ratio of radiation and chemotherapy. Our research program uses these models to identify targets that will allow better tailored radiation therapy and chemotherapy, by enhancing tumor responses to therapy and minimizing radiation- and chemotherapy-induced side effects, specifically treatment-induced cardiotoxicity. Our tumor studies are specifically focusing on the role of the tumor microenvironment in breast cancer treatment responses. The goals of these studies are to identify predictive and prognostic features of breast cancer to better classify and treat breast and other cancers, and ultimately to identify new treatment strategies to improve patient outcomes.